NCT02911857View on ClinicalTrials.gov

An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes

PHASE3CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

October 3, 2016

Primary Completion Date

January 27, 2017

Study Completion Date

January 27, 2017

Conditions
Periodic Fevers Syndrome
Interventions
BIOLOGICAL

Canakinumab (AIN457)

Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution

Trial Locations (3)

812-8582

Novartis Investigative Site, Fukuoka

236-0004

Novartis Investigative Site, Yokohama

606-8507

Novartis Investigative Site, Kyoto

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY